This review distills LITMUS lessons on biomarker qualification to speed NAFLD/NASH drug development. cT1 (LiverMultiScan) was submitted to EMA/FDA for prognostic enrichment and now holds an FDA-accepted Biomarker Qualification Program, the first for a diagnostic enrichment biomarker in NASH trials, positioning cT1 to streamline recruitment and improve trial success.
Welcome to Perspectum Medical Education
You are entering a website that is scientific in nature and created for healthcare professionals.
Are you a healthcare professional?